DCTH - NASDAQ
Delcath Systems, Inc.
$10.80
+2.6%Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
At a Glance
Live SnapshotDelcath Systems, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Minimal operating profit suggests high operating costs or pricing challenges. Scalability is concerning.
Net Profit Margin
Minimal profitability after all expenses. Limited financial flexibility for reinvestment or shareholder returns.
Effective Tax Rate
Moderate tax rate typical for most corporations. Represents standard tax burden on profits.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Delcath Systems, Inc. Income Statement
DCTH • NASDAQ
| Delcath Systems, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
85.2M | 37.2M | 2.1M | 2.7M | 3.6M | 1.6M | 1.6M | 3.4M | 2.7M | 2M | 1.7M | 1.1M | 790K | 346K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||||||||||||
(11.8M) | (6.2M) | (635K) | (686K) | (671K) | (640K) | (719K) | (1M) | (701K) | (550K) | (462K) | (291K) | (464K) | (39K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
73.4M | 31M | 1.4M | 2M | 2.9M | 1M | 861K | 2.4M | 2M | 1.4M | 1.3M | 778K | 326K | 307K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | ||||||||||||||||||||
(72.8M) | (43.4M) | (39.6M) | (35.9M) | (27.4M) | (22.3M) | (20.8M) | (29.5M) | (20.2M) | (17.9M) | (16.5M) | (20.1M) | (33.3M) | (54.2M) | (46.5M) | (30.7M) | (13.5M) | (8.1M) | (6.9M) | (11.7M) | |
(43.5M) | (29.6M) | (22.1M) | (17.3M) | (13.6M) | (11.1M) | (11.3M) | (9.8M) | (9.7M) | (9.4M) | (10M) | (15.8M) | (20.7M) | (28M) | (21.3M) | (13.2M) | (3.9M) | (2.7M) | (2.7M) | (9M) | |
(29.2M) | (13.9M) | (17.5M) | (18.6M) | (13.8M) | (11.2M) | (9.5M) | (19.7M) | (10.5M) | (8.4M) | (6.5M) | (4.3M) | (12.7M) | (26.2M) | (25.2M) | (17.6M) | (9.6M) | (5.4M) | (4.2M) | (2.7M) | |
660K | -12.4M | -38.2M | -33.9M | -24.5M | -21.3M | -19.9M | -27.1M | -18.2M | -16.4M | -15.2M | -19.3M | -33M | -53.9M | -46.5M | -30.7M | -13.5M | -8.1M | -6.9M | -11.7M | |
PRE-TAX INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (1.4M) | (2.7M) | (1.2M) | (175K) | (4.7M) | (8M) | (21.7M) | (14.3M) | (67K) | (24K) | (81K) | (175K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
2.9M | 0.0 | -1.4M | -2.7M | -1.2M | -175K | -4.7M | -8M | -21.7M | -14.3M | -67K | -19K | -61K | 19K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (2K) | (51K) | -41K | (0.0) | -67K | -24K | -81K | -175K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
2.9M | -14M | -9.5M | -2.7M | -1.1M | -2.9M | 11M | 7.8M | -27M | -1.5M | 506K | 1.9M | 2.7M | 2M | 15.6M | -15.9M | -8.5M | -6.9B | 3.2M | 126.5K | |
3.5M | -26.4M | -47.7M | -36.5M | -25.6M | -24.2M | -8.9M | -19.2M | -45.1M | -18M | -14.7M | -17.4M | -30.3M | -51.9M | -30.9M | -46.7B | -22.1B | -6.9B | -3.7B | -11.6M | |
NET INCOME | ||||||||||||||||||||
(810K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (4.7M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (81K) | (175K) | (0.0) | (15.9M) | (8.5M) | -6.9B | -3.2M | -746.9K | |
2.7M | -26.4M | -47.7M | -36.5M | -25.6M | -24.2M | -13.6M | -19.2M | -45.1M | -18M | -14.7M | -17.4M | -30.3M | -51.9M | -30.9M | -46.7M | -22.1M | -6.9M | -3.7M | -11M |
SEC Filings
DCTH - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 14, 2026 | May 13, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 02, 2026 | May 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 09, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 20, 2025 | November 19, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 |
Related Guides
Continue your DCTH research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.